Chroma: turning CRISPR on the epigenome

The debut of Chroma marks the advent of epigenetic editing, which holds the promise of precise control of gene expression, but without directly cutting or mutating DNA and the safety risks that come with those approaches.

Chroma Medicine Inc. officially launched last year with technology based on the work of scientific co-founders from Massachusetts General Hospital and University of California San Francisco, including some of the biggest names in CRISPR research, such as David Liu and Jonathan Weissman. The newco’s other scientific founders include Luke Gilbert, Keith Joung, Angelo Lombardo and Luigi Naldini...